Live from the NIH registry
Studies recruiting near Tulsa right now
Top 25 of 194 recruiting studies, sorted by proximity — each links to its official registry page
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Endometrial Cancer
Phase 2, Phase 3
Interventional 268 participants sought
Oklahoma Cancer Specialists and Research Institute — Tulsa, Oklahoma (5.3 mi)
· Sponsor: Kartos Therapeutics, Inc.
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa
Phase 2
Interventional 144 participants sought
Essential Medical Research- Site Number : 8400015 — Tulsa, Oklahoma (5.3 mi)
· Sponsor: Sanofi
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Acute Migraine
Phase 3
Interventional 1,000 participants sought
DelRicht Research — Tulsa, Oklahoma (5.3 mi)
· Sponsor: TriGemX Bio, Inc.
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Phase 3
Interventional 1,875 participants sought
Saint Francis Children's Hospital — Tulsa, Oklahoma (5.3 mi)
· Sponsor: National Cancer Institute (NCI)
Amplification of Positivity for Alcohol Use
Alcohol Use Disorder, Anxiety
N/A
Interventional 100 participants sought
Laureate Institute for Brain Research — Tulsa, Oklahoma (5.3 mi)
· Sponsor: Laureate Institute for Brain Research, Inc.
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Schizophrenia
N/A
Observational 1,500 participants sought
Local Institution - 0052 — Tulsa, Oklahoma (5.3 mi)
· Sponsor: Bristol-Myers Squibb
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Fibromyalgia
Phase 3
Interventional 620 participants sought
Clinical Research Site — Tulsa, Oklahoma (5.3 mi)
· Sponsor: Axsome Therapeutics, Inc.
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
Aortic Valve Insufficiency, Aortic Valve Stenosis
N/A
Interventional 200 participants sought
Oklahoma Heart Institute — Tulsa, Oklahoma (5.3 mi)
· Sponsor: Edwards Lifesciences
Beta-Adrenergic Modulation of Drug Cue Reactivity
Tobacco Use Disorder, Nicotine Dependence
Phase 4
Interventional 80 participants sought
Hardesty Center for Clinical Research and Neuroscience — Tulsa, Oklahoma (5.3 mi)
· Sponsor: University of Oklahoma
Modified Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of Hard-to-Heal DFUs
Diabetic Foot Ulcer (DFU), Ulcer Foot
N/A
Interventional 272 participants sought
Wound Care of Tulsa — Tulsa, Oklahoma (5.3 mi)
· Sponsor: StimLabs
A Phase 2 Study of NT-101 Topical in Patients With Wet AMD
Wet Age Related Macular Degeneration
Phase 2
Interventional 66 participants sought
Tulsa Retina Consultants — Tulsa, Oklahoma (5.3 mi)
· Sponsor: NexThera Co., Ltd.
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Phase 3
Interventional 1,295 participants sought
Oklahoma Cancer Specialists and Research Institute-Tulsa — Tulsa, Oklahoma (5.3 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Pan-tumor MRD Study
Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer
N/A
Observational 1,350 participants sought
Oklahoma Cancer Specialists and Research Institute (OCSRI) — Tulsa, Oklahoma (5.3 mi)
· Sponsor: Paradigm Health
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
Bacterial Conjunctivitis
Phase 3
Interventional 400 participants sought
Baxis Site 25 — Tulsa, Oklahoma (5.3 mi)
· Sponsor: Baxis Pharmaceuticals, Inc.
Empowered Relief® for Cancer Survivors With Chronic Pain
Chronic Pain Due to Cancer, Pain Catastrophizing
N/A
Interventional 215 participants sought
University of Oklahoma Schusterman Center - Tulsa — Tulsa, Oklahoma (5.3 mi)
· Sponsor: University of Oklahoma
Oklahoma Study of Native American Pain Risk III: Stress and Resilience
Discrimination, Racial, Stress Physiology
N/A
Observational 220 participants sought
University of Oklahoma - Schusterman Center — Tulsa, Oklahoma (5.3 mi)
· Sponsor: University of Oklahoma
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Psoriatic Arthritis, Overweight or Obesity
Phase 4
Interventional 200 participants sought
Essential Medical Research — Tulsa, Oklahoma (5.3 mi)
· Sponsor: Eli Lilly and Company
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Macular Degeneration, Age-Related Macular Degeneration
Phase 2, Phase 3
Interventional 960 participants sought
Tulsa Retina Consultants — Tulsa, Oklahoma (5.3 mi)
· Sponsor: EyeBiotech Ltd.
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Treatment Resistant Depression
N/A
Interventional 6,800 participants sought
University of Oklahoma School of Community Medicine — Tulsa, Oklahoma (5.3 mi)
· Sponsor: LivaNova
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Prostate Cancer, Prostatic Neoplasms
Phase 3
Interventional 383 participants sought
Urologic Specialists — Tulsa, Oklahoma (5.3 mi)
· Sponsor: Clarity Pharmaceuticals Ltd
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Parkinson Disease, Parkinson
Phase 2
Interventional 150 participants sought
The Movement Disorder Clinic of Oklahoma — Tulsa, Oklahoma (5.3 mi)
· Sponsor: Neuron23 Inc.
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Obesity or Overweight
Phase 3
Interventional 2,000 participants sought
Delricht Research of Tulsa Clinical Trials — Tulsa, Oklahoma (5.3 mi)
· Sponsor: Hoffmann-La Roche
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
Oklahoma Cancer Specialists and Research Institute-Tulsa — Tulsa, Oklahoma (5.3 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Osteoarthritis, Knee, Diabetic Neuropathic Pain
Phase 2
Interventional 10,000 participants sought
DelRicht Research — Tulsa, Oklahoma (5.3 mi)
· Sponsor: Eli Lilly and Company
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
Phase 3
Interventional 600 participants sought
Research Site — Tulsa, Oklahoma (5.3 mi)
· Sponsor: AstraZeneca